View in EDS

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

Saved in:
Bibliographic Details
Title: Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Authors: Zandberg, Dan P.1 zandbergdp@upmc.edu, Algazi, Alain P.2, Jimeno, Antonio3, Good, James S.4, Fayette, Jérôme5, Bouganim, Nathaniel6, Ready, Neal E.7, Clement, Paul M.8, Even, Caroline9, Jang, Raymond W.10, Wong, Stuart11, Keilholz, Ulrich12, Gilbert, Jill13, Fenton, Moon14, Braña, Irene15, Henry, Stephanie16, Remenar, Eva17, Papai, Zsuzsanna18, Siu, Lillian L.10, Jarkowski, Anthony1,19
Source: European Journal of Cancer. Jan2019, Vol. 107, p142-152. 11p.
Database: Academic Search Ultimate
Description
ISSN:09598049
DOI:10.1016/j.ejca.2018.11.015